Loading viewer...
investor_presentation
Format: PDF investor_presentation
Jasper Therapeutics presents its clinical validation strategy for Briquilimab, an anti c-Kit antibody candidate in development for acute and chronic mast and stem cell diseases. The company has demonstrated clinical validation across five transplant indications (AML, MDS, SCID, SCD, FA) and is expanding into chronic disease areas including chronic spontaneous urticaria with multiple near-term data catalysts expected through 2024.
presentation
investor_presentation
38 Pages
Qualcomm
investor_presentation
Allianz SE
investor_presentation
PAVmed